NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Carson S, McDonagh MS, Thakurta S, et al. Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet]. Portland (OR): Oregon Health & Science University; 2008 Oct.

Cover of Drug Class Review: Newer Drugs for Insomnia

Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet].

Show details

References

1.
Buscemi N, Vandermeer B, Friesen C, et al. Manifestations and management of chronic insomnia in adults Evidence report/technology assessment No 125. Rockville, MD: Prepared by the University of Alberta Evidence-based Practice Center; 2005.
2.
Ancoli-Israel S, Cooke JR. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. Journal of the American Geriatrics Society. 2005 Jul;53(Suppl 7):S264–271. [PubMed: 15982375]
3.
Anonymous. Diagnostic and statistical manual of mental disorders : DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
4.
Schenck CH, Mahowald MW, Sack RL. Assessment and Management of Insomnia . Journal of the American Medical Association. 2003;289(19):2475–2479. [PubMed: 12759306]
5.
6.
Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews CRD Report Number 4. 2nd edition. York, UK: NHS Centre for Reviews and Dissemination; 2001. p. 4.
7.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the third U.S. Preventive Services Task Force . American Journal of Preventive Medicine. 2001;20(Suppl 3):21–35. [PubMed: 11306229]
8.
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta analysis of randomized controlled trials . Journal of Clinical Epidemiology. 1997;50(6):683–691. [PubMed: 9250266]
9.
Glenny AM, Altman DG, Fea Song. Indirect comparisons of competing interventions . Health Technology Assessment. 2005;9(26):1–134. [PubMed: 16014203]
10.
Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect analyses. Lancet. 2006;368:1503–1515. [PubMed: 17071284]
11.
Song F, Altman DG, Glenny AM, Deeks J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. British Medical Journal. 2003;326(7387):472. [PMC free article: PMC150178] [PubMed: 12609941]
12.
Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodizepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects . Primary Care. 1999;1:114–120. [PMC free article: PMC181075] [PubMed: 15014684]
13.
Lemoine P, Allain H, Janus C, Sutet P. Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months . European Psychiatry. 1995;10(Suppl 3):161S–165S. [PubMed: 19698413]
14.
Elie R, Ruther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group . Journal of Clinical Psychiatry. 1999;60(8):536–544. [PubMed: 10485636]
15.
Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group . International Clinical Psychopharmacology. 2000;15(3):141–152. [PubMed: 10870872]
16.
Tsutsui S, Zolipidem Study G. A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia . Journal of International Medical Research. 2001;29(3):163–177. [PubMed: 11471853]
17.
Allain H, Bentue-Ferrer D, Breton SL, Polard E, Gandon JM. Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg . Human Psychopharmacology. 2003;18(5):369–374. [PubMed: 12858323]
18.
Erman MK, Walsh JK, Wessel TC, Caron J, Amato D. A crossover study of eszopiclone in the treatment of primary insomnia [poster]. Paper presented at: American Psychiatric Association Meeting Poster Session; 2005.
19.
Staner L, Ertle S, Boeijinga P, et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring . Psychopharmacology. 2005 Oct;181(4):790–798. [PubMed: 16025317]
20.
21.
Agnoli A, Manna V, Martucci N. Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia . International Journal of Clinical Pharmacology Research. 1989;9(4):277–281. [PubMed: 2674029]
22.
Anderson AA. Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice . Sleep. 1987;10(1):54–62. [PubMed: 3326116]
23.
Ansoms S, Lebon O, Pelc I, Cabri C, Poels R. Zopiclone or lormetazepam in the treatment of insomnia and the effect on behavior and mood in patients during the postalcoholism withdrawal period . Current Therapeutic Research - Clinical and Experimental. 1991;49(1):54–64.
24.
Autret E, Maillard F, Autret A. Comparison of the clinical hypnotic effects of zopiclone and triazolam . European Journal of Clinical Pharmacology. 1987;31(5):621–623. [PubMed: 3549323]
25.
Begg EJ, Robson RA, Frampton CM, Campbell JE. A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone . New Zealand Medical Journal. 1992;105(944):428–429. [PubMed: 1297939]
26.
Bergener M, Gola R, Hesse C. The influence of age-dependent pharmacokinetics on the pharmacodynamics of hypnotic drugs: comparison of two hypnotics with different half-lives . International Psychogeriatrics. 1989;1(1):17–29. [PubMed: 2490902]
27.
Bozin-Juracic J. Pharmacotherapy of transient insomnia related to night work . Arhiv Za Higijenu Rada i Toksikologiju. 1996;47(2):157–165. [PubMed: 8905934]
28.
Chaudoir PJ, Bodkin NL, O'Donnell J, Anderson A, Holland RL. A comparative study of zopiclone and triazolam in patients with insomnia . International Clinical Psychopharmacology. 1990;5(2):21–27. [PubMed: 2201727]
29.
Drake CL, Roehrs TA, Mangano RM, Roth T. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia . Human Psychopharmacology. 2000;15(8):595–604. [PubMed: 12404612]
30.
Elie R, Frenay M, Le Morvan P, Bourgouin J. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs . International Clinical Psychopharmacology. 1990a;5(2):39–46. [PubMed: 2201729]
31.
Elie R, Lavoie G, Bourgouin J, Le Morvan P. Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal . International Clinical Psychopharmacology. 1990b;5(4):279–286. [PubMed: 2081899]
32.
Fleming J, Moldofsky H, Walsh JK, Scharf M, Nino MG, Radonjic D. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia . Clinical Drug Investigation. 1995;9(6):303–313.
33.
Fleming JA, McClure DJ, Mayes C, Phillips R, Bourgouin J. A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia . International Clinical Psychopharmacology. 1990;5(2):29–37. [PubMed: 2201728]
34.
Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety . International Clinical Psychopharmacology. 1990;5(3):173–183. [PubMed: 2230061]
35.
Hajak G, Clarenbach P, Fischer W, et al. Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia . European Psychiatry. 1995;10(Suppl 3):173S–179S. [PubMed: 19698415]
36.
Hajak G, Clarenbach P, Fischer W, Haase W, Ruther E. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo . International Clinical Psychopharmacology. 1994;9(4):251–261. [PubMed: 7868847]
37.
Hajak G, Clarenbach P, Fischer W, et al. Rebound insomnia after hypnotic withdrawal in insomniac outpatients . European Archives of Psychiatry & Clinical Neuroscience. 1998;248(3):148–156. [PubMed: 9728734]
38.
Hayoun G, Bagot C. Comparative efficacy and safety of triazolam and zopiclone in insomniacs seen in general practice . Current Therapeutic Research - Clinical and Experimental. 1989;46(6):1236–1244.
39.
Klimm HD, Dreyfus JF, Delmotte M. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia . Sleep. 1987;10(1):73–78. [PubMed: 3326118]
40.
Leppik IE, Roth-Schechter GB, Gray GW, Cohn MA, Owens D. Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia . Drug Development Research. 1997;40(3):230–238.
41.
Li Pi Shan RS, Ashworth NL. Comparison of lorazepam and zopiclone for insomnia in patients with stroke and brain injury: a randomized, crossover, double-blinded trial . American Journal of Physical Medicine & Rehabilitation. 2004;83(6):421–427. [PubMed: 15166685]
42.
Liu CY, Yang YY, Yeh EK. Efficacy and side effects of zopiclone and triazolam in the treatment of Chinese patients with insomnia - A double blind cross-over study . International Medical Journal. 1997;4(1):45–48.
43.
Mamelak M, Buck L, Csima A, Price V, Smiley A. Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction . Sleep. 1987;10(1):79–87. [PubMed: 3438646]
44.
Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients . Pharmacopsychiatry. 1994;27(4):166–175. [PubMed: 7972349]
45.
Nair NP, Schwartz G, Dimitri R, Le Morvan P, Thavundayil JX. A dose-range finding study of zopiclone in insomniac patients . International Clinical Psychopharmacology. 1990;5(2):1–10. [PubMed: 2201721]
46.
Ngen CC, Hassan R. A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia . International Clinical Psychopharmacology. 1990;5(3):165–171. [PubMed: 2230060]
47.
Pagot R, Cramer P, L'Heritier C, Coquelin J-P, Attali P. Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients . Current Therapeutic Research - Clinical and Experimental. 1993;53(1):88–97.
48.
Ponciano E, Freitas F, Camara J, Faria M, Barreto M, Hindmarch I. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients . International Clinical Psychopharmacology. 1990;5(2):69–77. [PubMed: 2201731]
49.
Quadens OP, Hoffman G, Buytaert G. Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age . Pharmacology. 1983;27(Suppl 2):146–155. [PubMed: 6366818]
50.
Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia . Clinical Therapeutics. 1993;15(1):127–136. [PubMed: 8458042]
51.
Rosenberg J, Ahlstrom F. Randomized, double blind trial of zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice . Scandinavian Journal of Primary Health Care. 1994;12(2):88–92. [PubMed: 7973199]
52.
Schwartz T, Nihalani N, Virk S, et al. "A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia" . International Journal of Psychiatric Nursing Research. 2004 Aug;10(1):1146–1150. [PubMed: 15468607]
53.
Silvestri R, Ferrillo F, Murri L, et al. Rebound insomnia after abrupt discontinuation of hypnotic treatment: Double-blind randomized comparison of zolpidem versus triazolam . Human Psychopharmacology. 1996;11(3):225–233.
54.
Singh AN, Bourgouin J. Comparison of zopiclone and flurazepam treatments in insomnia . Human Psychopharmacology. 1990;5(3):217–223.
55.
Steens RD, Pouliot Z, Millar TW, Kryger MH, George CF. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease . Sleep. 1993;16(4):318–326. [PubMed: 8341892]
56.
Stip E, Furlan M, Lussier I, Bourgouin P, Elie R. Double-blind, placebo-controlled study comparing effects of zopiclone and temazepam on cognitive functioning of insomniacs . Human Psychopharmacology. 1999;14(4):253–261.
57.
Tamminen T, Hansen PP. Chronic administration of zopiclone and nitrazepam in the treatment of insomnia . Sleep. 1987;10(1):63–72. [PubMed: 3326117]
58.
van der Kleijn E. Effects of zopiclone and temazepam on sleep, behaviour and mood during the day . European Journal of Clinical Pharmacology. 1989;36(3):247–251. [PubMed: 2744064]
59.
Venter CP, Joubert PH, Stahmer SD, et al. Zopliclone compared with triazolam in insomnia in geriatric patients . Current Therapeutic Research - Clinical and Experimental. 1986;40(6):1062–1068.
60.
Voshaar RC, van Balkom AJ, Zitman FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study . European Neuropsychopharmacology. 2004;14(4):301–306. [PubMed: 15163440]
61.
Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia . Human Psychopharmacology. 1998a;13:191–198.
62.
Walsh JK, Fry J, Erwin CW, Scharf M, Roth T, Vogel GW. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia . Clinical Drug Investigation. 1998b;16(5):347–354.
63.
Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia . Clinical Neuropharmacology. 2000;23(1):17–21. [PubMed: 10682226]
64.
Ware JC, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10-mg zolpidem . Clinical Neuropharmacology. 1997;20(2):116–125. [PubMed: 9099463]
65.
Wheatley D. Zopiclone: a non-benzodiazepine hypnotic. Controlled comparison to temazepam in insomnia . British Journal of Psychiatry. 1985;146:312–314. [PubMed: 2859069]
66.
Allain H, Arbus L, Schuck S, et al. Efficacy and safety of zolpidem administered 'as needed' in primary insomnia: Results of a double-blind, placebo-controlled study . Clinical Drug Investigation. 2001;21(6):391–400.
67.
Allain H, Le Coz F, Borderies P, et al. Use of zolpidem 10 mg as a benzodiazepine substitute in 84 patients with insomnia . Human Psychopharmacology. 1998;13(8):551–559.
68.
Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients . Journal of Clinical Psychiatry. 1999;60(10):668–676. [PubMed: 10549683]
69.
Berry RB, Patel PB. Effect of zolpidem on the efficacy of continuous positive airway pressure as treatment for obstructive sleep apnea . Sleep. 2006 Aug 1;29(8):1052–1056. [PubMed: 16944674]
70.
Besset A, Tafti M, Villemin E, Borderies P, Billiard M. Effects of zolpidem on the architecture and cyclical structure of sleep in poor sleepers . Drugs under Experimental and Clinical Research. 1995;21(4):161–169. [PubMed: 8529530]
71.
Chaudoir PJ, Jarvie NC, Wilcox GJ. The acceptability of a non-benzodiazepine hypnotic (Zopiclone) in general practice . Journal of International Medical Research. 1983;11(6):333–337. [PubMed: 6360747]
72.
Declerck A, Smits M. Zolpidem, a valuable alternative to benzodiazepine hypnotics for chronic insomnia [erratum appears in J Int Med Res 2000;28(1):46] Journal of International Medical Research. 1999;27(6):253–263. [PubMed: 10726234]
73.
Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial . Clinical Neuropharmacology. 1996;19(4):333–340. [PubMed: 8828996]
74.
Dorsey CM, Lee KA, Scharf MB. Effect of Zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: A 4-week, randomized, multicenter, double-blind, placebo-controlled study . Clinical Therapeutics. 2004;26(10):1578–1586. [PubMed: 15598474]
75.
Drewes AM, Andreasen A, Jennum P, Nielsen KD. Zopiclone in the treatment of sleep abnormalities in fibromyalgia . Scandinavian Journal of Rheumatology. 1991;20(4):288–293. [PubMed: 1925417]
76.
Drewes AM, Bjerregard K, Taagholt SJ, Svendsen L, Nielsen KD. Zopiclone as night medication in rheumatoid arthritis . Scandinavian Journal of Rheumatology. 1998;27(3):180–187. [PubMed: 9645412]
77.
Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia . Sleep Medicine. 2006 Jan;7(1):17–24. [PubMed: 16309958]
78.
Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder . Biological Psychiatry. 2006 Jun 1;59(11):1052–1060. [PubMed: 16581036]
79.
FDA. Statistical review of zolpidem extended release. http://www​.fda.gov/cder​/foi/nda/2005/021774s000_AmbienTOC​.htm .
80.
81.
Goldenberg F, Hindmarch I, Joyce CRB, Le GM, Partinen M, Pilate C. Zopiclone, sleep and health-related quality of life . Human Psychopharmacology. 1994;9(4):245–251.
82.
Gronblad M, Nykanen J, Konttinen Y, Jarvinen E, Helve T. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial . Clinical Rheumatology. 1993;12(2):186–191. [PubMed: 8358976]
83.
Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group . International Journal of Geriatric Psychiatry. 2000;15(8):704–712. [PubMed: 10960882]
84.
Herrmann WM, Kubicki ST, Boden S, Eich FX, Attali P, Coquelin JP. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation . Journal of International Medical Research. 1993;21(6):306–322. [PubMed: 8143886]
85.
Hindmarch I. Effects of zopiclone on quality of life in insomnia . European Psychiatry. 1995;10(Suppl 3):91S–94S. [PubMed: 19698402]
86.
Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea . Sleep & Breathing. 2007 Sep;11(3):159–164. [PubMed: 17294232]
87.
Kryger MH, Steljes D, Pouliot Z, Neufeld H, Odynski T. Subjective versus objective evaluation of hypnotic efficacy: Experience with zolpidem . Sleep. 1991;14(5):399–407. [PubMed: 1759092]
88.
Krystal A, Walsh J, Roth T, Rubens R, Wessel TC. Evaluation of the efficacy and safety of eszopiclone over six-months of treatment in patients with insomnia [poster]
89.
Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T, Group ZS. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study . Sleep. 2008 Jan 1;31(1):79–90. [PMC free article: PMC2225552] [PubMed: 18220081]
90.
Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793–799. [see comment] [PubMed: 14655910]
91.
Lahmeyer H, Wilcox CS, Kann J, Leppik I. Subjective efficacy of zolpidem in outpatients with chronic insomnia: A double-blind comparison with placebo . Clinical Drug Investigation. 1997;13(3):134–144.
92.
Lofaso F, Goldenberg F, Thebault C, Janus C, Harf A. Effect of zopiclone on sleep, night-time ventilation, and daytime vigilance in upper airway resistance syndrome . European Respiratory Journal. 1997;10(11):2573–2577. [PubMed: 9426097]
93.
McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia . Current Medical Research & Opinion. 2006 Sep;22(9):1633–1642. [PubMed: 16968566]
94.
Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty . American Journal Geriatric Pharmacotherapy. 2007 Sep;5(3):177–184. [PubMed: 17996657]
95.
Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. Journal of Rheumatology. 1996;23(3):529–533. [see comment] [PubMed: 8832997]
96.
Monchesky TC, Billings BJ, Phillips R. Zopiclone: a new nonbenzodiazepine hypnotic used in general practice . Clinical Therapeutics. 1986;8(3):283–291. [PubMed: 3521857]
97.
Monchesky TC, Billings BJ, Phillips R, Bourgouin J. Zopiclone in insomniac shiftworkers. Evaluation of its hypnotic properties and its effects on mood and work performance . International Archives of Occupational & Environmental Health. 1989;61(4):255–259. [PubMed: 2656527]
98.
Monti JM, Alvarino F, Monti D. Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia . Sleep. 2000;23(8):1075–1084. [PubMed: 11145322]
99.
Monti JM, Monti D, Estevez F, Giusti M. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal . International Clinical Psychopharmacology. 1996;11(4):255–263. [PubMed: 9031992]
100.
Parrino L, Smerieri A, Giglia F, Milioli G, De Paolis F, Terzano MG. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia . Clinical Neuropharmacology. 2008 Jan-Feb;31(1):40–50. [PubMed: 18303490]
101.
Pecknold J, Wilson R, le Morvan P. Long term efficacy and withdrawal of zopiclone: a sleep laboratory study . International Clinical Psychopharmacology. 1990;5( Suppl 2):57–67. [PubMed: 2117623]
102.
Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia . Journal of Clinical Psychiatry. 2004;65(8):1128–1137. [PubMed: 15323600]
103.
Roehrs T, Soubrane C, Walsh J, Roth T. Efficacy and safety of 625 mg of zolpidem modified release formulation in elderly patients with primary insomnia (poster). Presented at 158th American Psychiatric Association Meeting; Miami, FL. May 21-23, 2005; 2005.
104.
Rosenberg R, Roach JM, Scharf M, Amato DA. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome . Sleep Medicine. 2007 Aug;8(5):464–470. [PubMed: 17512799]
105.
Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia . Sleep Medicine. 2006 Jun;7(4):312–318. [PubMed: 16709464]
106.
Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia . Current Medical Research & Opinion. 2007 May;23(5):1005–1014. [PubMed: 17519067]
107.
Roth T, Soubrane C, Titeux L, Walsh JK, Zoladult Study G. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia . Sleep Medicine. 2006 Aug;7(5):397–406. [PubMed: 16815744]
108.
Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia . Sleep Medicine. 2005;6(6):487–495. [PubMed: 16230048]
109.
Sabbatini M, Crispo A, Pisani A, et al. Zaleplon improves sleep quality in maintenance hemodialysis patients . Nephron Clinical Practice. 2003;94(4):c99–103. [PubMed: 12972720]
110.
Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia . Sleep. 2005;28(6):714–799. [PubMed: 16477959]
111.
Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia . Journal of Clinical Psychiatry. 1994;55(5):192–199. [PubMed: 8071269]
112.
Schnitzer T, Rubens R, Price J, Wessel TC. The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia [poster]
113.
Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients.[erratum appears in J Int Med Res 1992 Nov;20(6):following 494] Journal of International Medical Research. 1992;20(2):150–161. [PubMed: 1521671]
114.
Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial . Obstetrics & Gynecology. 2006 Dec;108(6):1402–1410. [PubMed: 17138773]
115.
Soubrane C, Walsh J, Roth T. Efficacy and safety of 125 mg of zolpidem modified release formulation in adult patients with primary insomnia (poster). Presented at 158th American Psychiatric Association Meeting; Miami, FL. May 21-23, 2005; 2005.
116.
Terzano MG, Parrino L. Evaluation of EEG cyclic alternating pattern during sleep in insomniacs and controls under placebo and acute treatment with zolpidem . Sleep. 1992;15(1):64–70. [PubMed: 1557595]
117.
Walsh JK. Zolpidem "as needed" for the treatment of primary insomnia: a double-blind, placebo-controlled study. Sleep Medicine Reviews. 2002;6(1):S7–S11. [see comment] [PubMed: 12607571]
118.
Walsh JK, Fry J, Richardson GS, Scharf MB, Vogel GW. Short-term efficacy of zaleplon in older patients with chronic insomnia . Clinical Drug Investigation. 2000a;20(3):143–149.
119.
Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations . Sleep. 2007 Aug 1;30(8):959–968. [PMC free article: PMC1978384] [PubMed: 17702264]
120.
Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia . Sleep. 2000b;23(8):1087–1096. [PubMed: 11145323]
121.
Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients . American Journal of Geriatric Psychiatry. 2008 Jan;16(1):44–57. [PubMed: 18165461]
122.
Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.[erratum appears in J Clin Sleep Med. 2007 Oct 15;3(6):table of contents] Journal of Clinical Sleep Medicine. 2007 Aug 15;3(5):495–504. [PMC free article: PMC1978328] [PubMed: 17803013]
123.
Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia . Current Medical Research and Opinion. 2004;20(12):1979–1991. [PubMed: 15701215]
124.
Dundar Y, Boland A, Strobl J, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technology Assessment. 2004;8(24):140. [PubMed: 15193209]
125.
Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds III CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy . Journal of the American Medical Association. 1997;278(24):2170–2177. [PubMed: 9417012]
126.
Glass J, Lanctãot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits . British Medical Journal. 2005 Nov 19;331(7526):1169. [PMC free article: PMC1285093] [PubMed: 16284208]
127.
Allain H, Delahaye C, Le Coz F, Blin P, Decombe R, Martinet JP. Postmarketing surveillance of zopiclone in insomnia: Analysis of 20,513 cases . Sleep. 1991;14(5):408–413. [PubMed: 1759093]
128.
Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS. Long-term use of sedative hypnotics in older patients with insomnia . Sleep Medicine. 2005;6(2):107–113. [PubMed: 15716214]
129.
Bain KT, Weschules DJ, Knowlton CH, Gallagher R. Toward evidence-based prescribing at end of life: a comparative review of temazepam and zolpidem for the treatment of insomnia . American Journal of Hospice & Palliative Care. 2003 Sep-Oct;20(5):382–388. [PubMed: 14529041]
130.
Buckley NA, McManus PR. Changes in Fatalities Due to Overdose of Anxiolytic and Sedative Drugs in the UK (1983–1999) Drug Safety. 2004;27(2):135–141. [PubMed: 14717623]
131.
Delahaye C, Ferrand B, Pieddeloup C, Musch B. Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice . International Clinical Psychopharmacology. 1990;5( Suppl 2):131–138. [PubMed: 2201725]
132.
Devins GM, Flanigan M, Fleming JAE, et al. Differential illness intrusiveness associated with sleep-promoting medications . European Psychiatry. 1995;10(Suppl 3):153S–159S. [PubMed: 19698412]
133.
Diav-Citrin O, Okotore B, Lucarelli K, Koren G. Pregnancy outcome following first-trimester exposure to zopiclone: A prospective controlled cohort study . American Journal of Perinatology. 1999;16(4):157–160. [PubMed: 10458526]
134.
Ganzoni E, Santoni Ph J, Chevillard V, Sebille M, Mathy B. Zolpidem in insomnia: A 3-year post-marketing surveillance study in Switzerland . Journal of International Medical Research. 1995;23(1):61–73. [PubMed: 7774760]
135.
Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16 944 cases . International Clinical Psychopharmacology. 1998;13(4):157–167. [PubMed: 9727726]
136.
Jaffe JH, Bloor R, Crome I, et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs . Addiction. 2004;99(2):165–173. [PubMed: 14756709]
137.
Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: A long-term open study in general practice . Journal of International Medical Research. 1992;20(2):162–170. [PubMed: 1521672]
138.
Morishita S, Sonohara M, Murakami H, Yoshida S, Aoki S. Long-term treatment of brotizolam and zopiclone in elderly insomniacs . Kawasaki Medical Journal. 2000;26(1):9–11.
139.
Peeters K, Boucau M, De Bouyalsky I, Van Reeth O. Efficacy and safety of a one-month treatment with zolpidem in middle-aged and elderly insomniacs . Acta Therapeutica. 1997;23(1–2):5–19.
140.
Reith DM, Fountain J, McDowell R, Tilyard M. Comparison of the Fatal Toxicity Index of Zopiclone with Benzodiazepines . Journal of Toxicology - Clinical Toxicology. 2003;41(7):975–980. [PubMed: 14705844]
141.
Scharf MB, Mendels J, Thorpy M, Weiss B. Safety of long-term zolpidem treatment in patients with insomnia . Current Therapeutic Research - Clinical and Experimental. 1994;55(9):1100–1111.
142.
Schlich D, L'Heritier C, Coquelin JP, Attali P. Long-term treatment of insomnia with zolpidem: A multicentre general practitioner study of 107 patients . Journal of International Medical Research. 1991;19(3):271–279. [PubMed: 1670039]
143.
Schneeweiss S, Wang PS. Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information . Journal of the American Geriatrics Society. 2005 Jun;53(6):948–954. [PubMed: 15935016]
144.
Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey . British Journal of Clinical Pharmacology. 2007 Aug;64(2):198–209. [PMC free article: PMC2000636] [PubMed: 17324242]
145.
Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people . Journal of the American Geriatrics Society. 2001;49(12):1685–1690. [PubMed: 11844004]
146.
Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England . British Journal of Obstetrics and Gynaecology. 1998;105(8):882–889. [PubMed: 9746382]
147.
Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia . Journal of Clinical Sleep Medicine. 2008;4(3):229–234. [PMC free article: PMC2546455] [PubMed: 18595435]
148.
Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006 Jun 28;295(24):2851–2858. [see comment] [PubMed: 16804151]
149.
Aragona M. Abuse, dependence, and epileptic seizures after zolpidem withdrawal: Review and case report . Clinical Neuropharmacology. 2000;23(5):281–283. [PubMed: 11154097]
150.
Aranko K, Henriksson M, Hublin C, Seppalainen AM. Misuse of zopiclone and convulsions during withdrawal . Pharmacopsychiatry. 1991;24(4):138–140. [PubMed: 1754610]
151.
Bottlender R, Schutz C, Moller H-J, Soyka M. Zolpidem dependence in a patient with former polysubstance abuse. Pharmacopsychiatry. 1997;30:103. 108%N. [PubMed: 9211573]
152.
Jones IR, Sullivan G. Physical dependence on zopiclone: Case reports. British Medical Journal. 1998;316:7125. 117%N. [PMC free article: PMC2665371] [PubMed: 9462317]
153.
Liappas IA, Malitas PN, Dimopoulos NP, et al. Zolpidem dependence case series: Possible neurobiological mechanisms and clinical management . Journal of Psychopharmacology. 2003;17(1):131–135. [PubMed: 12680751]
154.
Liappas IA, Malitas PN, Dimopoulos NP, et al. Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis . World Journal of Biological Psychiatry. 2003 Apr;4(2):93–96. [PubMed: 12692780]
155.
Ravishankar A, Carnwath T. Zolpidem tolerance and dependence - Two case reports . Journal of Psychopharmacology. 1998;12(1):103–104. [PubMed: 9584975]
156.
Sakkas P, Psarros C, Masdrakis V, Liappas J, Christodoulou GN. Dependence on zolpidem: A case report . European Psychiatry. 1999;14(6):358–359. [PubMed: 10572372]
157.
Sullivan G, McBride AJ, Clee WB. Zopiclone abuse in South Wales: Three case reports . Human Psychopharmacology. 1995;10(4):351–352.
158.
Vartzopoulos D, Bozikas V, Phocas C, Karavatos A, Kaprinis G. Dependence on zolpidem in high dose . International Clinical Psychopharmacology. 2000;15(3):181–182. [PubMed: 10870877]
159.
Gericke CA, Ludolph AC. Chronic abuse of zolpidem . Journal of the American Medical Association. 1994;272(22):1721–1722. [PubMed: 7966909]
160.
Haasen C, Mueller-Thomsen T, Fink T, Bussopulos A, Reimer J. Zopiclone dependence after insomnia related to torticollis . International Journal of Neuropsychopharmacology. 2005 Jun;8(2):309–310. [PubMed: 15631646]
161.
Kao CL, Huang SC, Yang YJ, Tsai SJ. A case of parenteral zolpidem dependence with opioid-like withdrawal symptoms . Journal of Clinical Psychiatry. 2004 Sep;65(9):1287. [PubMed: 15367062]
162.
Kuntze MF, Bullinger AH, Mueller-Spahn F. Excessive use of zopiclone: A case report . Swiss Medical Weekly. 2002;132:35–36. [PubMed: 12506335]
163.
Liappas IA, Malitas PN, Dimopoulos NP, et al. A zolpidem and cocaine abuse case report . International Journal of Psychiatry in Clinical Practice. 2002;6(4):217–219. [PubMed: 24937116]
164.
Madrak LN, Rosenberg M. Zolpidem abuse . American Journal of Psychiatry. 2001;158(8):1330–1331. [PubMed: 11481176]
165.
Quaglio G, Lugoboni F, Fornasiero A, Lechi A, Gerra G, Mezzelani P. Dependence on zolpidem: Two case reports of detoxification with flumazenil infusion . International Clinical Psychopharmacology. 2005 Sep;20(5):285–287. [PubMed: 16096519]
166.
Thakore J, Dinan TG. Physical dependence following zopiclone usage: A case report . Human Psychopharmacology. 1992;7(2):143–145.
167.
Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: A review of case reports and epidemiological data . Addiction. 2003;98(10):1371–1378. [PubMed: 14519173]
168.
Duggal HS. New-onset transient hallucinations possibly due to eszopiclone: a case study . Primary Care Companion to the Journal of Clinical Psychiatry. 2007;9(6):468–469. [PMC free article: PMC2139930] [PubMed: 18185832]
169.
Stillwell ME. Zaleplon and driving impairment . Journal of Forensic Sciences. 2003;48(3):677–679. [PubMed: 12762547]
170.
Bhatia SC, Arora M, Bhatia SK. Perceptual disturbances with zaleplon . Psychiatric Services. 2001;52(1):109–110. [PubMed: 11141544]
171.
Liskow B, Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior . Journal of the American Academy of Child & Adolescent Psychiatry. 2004;43(8):927–928. [PubMed: 15266187]
172.
Moloney I, Breen EG, El Hassan H, Kelly BD. Extreme agitation occurring with zopiclone . Irish Medical Journal. 2007 Jun;100(6):511. [PubMed: 17668690]
173.
Fava GA. Amnestic syndrome induced by zopiclone . European Journal of Clinical Pharmacology. 1996;50(6):509. [PubMed: 8858280]
174.
Stebbing J, Waters L, Davies L, et al. Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study . Journal of Clinical Oncology. 2005 Nov 1;23(31):8134–8136. [PubMed: 16258120]
175.
Bramness JG, Arnestad M, Karinen R, Hilberg T. Fatal overdose of zopiclone in an elderly woman with bronchogenic carcinoma . Journal of Forensic Sciences. 2001;46(5):1247–1249. [PubMed: 11569575]
176.
Wong CP, Chiu PKC, Chu LW. Zopiclone withdrawal: an unusual cause of delirium in the elderly . Age & Ageing. 2005 Sep;34(5):526–527. [PubMed: 16107464]
177.
Alderman CP, Gebauer MG, Gilbert AL, Condon JT. Possible interaction of zopiclone and nefazodone . Annals of Pharmacotherapy. 2001;35(11):1378–1380. [PubMed: 11724087]
178.
Vogel SD, Bayliff CD, George CFP. Zopiclone-associated respiratory depression . Canadian Journal of Hospital Pharmacy. 1998;51(2):58–60.
179.
Andrade C. Zolpidem, vascular headache, and hallucinations in an adolescent [3] Australian and New Zealand Journal of Psychiatry. 2002;36(3):425–426. [PubMed: 12060196]
180.
Brodeur MR, Stirling AL. Delirium associated with zolpidem . Annals of Pharmacotherapy. 2001;35(12):1562–1564. [PubMed: 11793620]
181.
Canaday BR. Amnesia possibly associated with zolpidem administration . Pharmacotherapy. 1996;16(4):687–689. [PubMed: 8840378]
182.
Cavallero R, Regazzetti MG, Covelli G, Smeraldi E. Tolerance and withdrawal with zolpidem . Lancet. 1993;342(8867):374–375. [PubMed: 8101619]
183.
Clark A. Worsening hepatic encephalopathy secondary to zolpidem . Journal of Pharmacy Technology. 1999;15(4):139–141.
184.
Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction . Journal of Toxicology - Clinical Toxicology. 1998;36(3):195–203. [PubMed: 9656974]
185.
Freudenreich O, Menza M. Zolpidem-related delirium: A case report . Journal of Clinical Psychiatry. 2000;61(6):449–450. [PubMed: 10901348]
186.
Ginsberg DL. Zolpidem-Induced Visual Distortions . Primary Psychiatry. 2003;10(11):16–17.
187.
Harazin J, Berigan TR. Zolpidem tartrate and somnambulism . Military Medicine. 1999 Sep;164(9):669–670. [PubMed: 10495642]
188.
Hill KP, Oberstar JV, Dunn ER. Zolpidem-induced delirium with mania in an elderly woman . Psychosomatics. 2004;45(1):88–89. [PubMed: 14709766]
189.
Hoyler CL, Tekell JL, Silva JA. Zolpidem-induced agitation and disorganization . General Hospital Psychiatry. 1996;18(6):452–453. [PubMed: 8937915]
190.
Huang C-L, Chang C-J, Hung C-F, Lin H-Y. Zolpidem-induced distortion in visual perception . Annals of Pharmacotherapy. 2003;37(5):683–686. [PubMed: 12708947]
191.
Karsenti D, Blanc P, Bacq Y, Melman EH. Hepatotoxicity associated with zolpidem treatment. British Medical Journal. 1999;318:7192. 1179%N. [PMC free article: PMC27854] [PubMed: 10221943]
192.
Lange CL. Medication-Associated Somnambulism . Journal of the American Academy of Child & Adolescent Psychiatry. 2005 Mar;44(3):211–212. [PubMed: 15725964]
193.
Logan BK, Couper FJ. Zolpidem and driving impairment . Journal of Forensic Sciences. 2001 Jan;46(1):105–110. [PubMed: 11210892]
194.
Markowitz JS, Brewerton TD. Zolpidem-induced psychosis . Annals of Clinical Psychiatry. 1996;8(2):89–91. [PubMed: 8807033]
195.
Markowitz JS, Rames LJ, Reeves N, Thomas SG. Zolpidem and hallucinations . Annals of Emergency Medicine. 1997;29(2):300–301. [PubMed: 9018205]
196.
Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem . Sleep Medicine. 2002;3(4):323–327. [PubMed: 14592194]
197.
Ortega L, Iruela LM, Ibanez-Rojo V, Baca E. Zolpidem after long-acting benzodiazepines: Possible interaction . Journal of Drug Development and Clinical Practice. 1996;8(1):45–46.
198.
Pies RW. Dose-related sensory distortions with zolpidem . Journal of Clinical Psychiatry. 1995;56(1):35–36. [PubMed: 7836339]
199.
Pitner JK, Gardner M, Neville M, Mintzer J. Zolpidem-induced psychosis in an older woman . Journal of the American Geriatrics Society. 1997;45(4):533–534. [PubMed: 9100733]
200.
Sattar SP, Ramaswamy S, Bhatia SC, Petty F. Somnambulism due to probable interaction of valproic acid and zolpidem . Annals of Pharmacotherapy. 2003;37(10):1429–1433. [PubMed: 14519043]
201.
Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment . Clinical Neuropharmacology. 2000;23(1):54–58. [PubMed: 10682233]
202.
Tripodianakis J, Potagas C, Papageorgiou P, Lazaridou M, Matikas N. Zolpidem-related epileptic seizures: A case report . European Psychiatry. 2003 May;18(3):140–141. [PubMed: 12763302]
203.
Tsai M-J, Huang Y-B, Wu P-C. A Novel Clinical Pattern of Visual Hallucination after Zolpidem Use . Journal of Toxicology - Clinical Toxicology. 2003;41(6):869–872. [PubMed: 14677799]
204.
Van Puijenbroek EP, Egberts ACG, Krom HJ. Visual hallucinations and amnesia associated with the use of zolpidem. International Journal of Clinical Pharmacology and Therapeutics. 1996;34:317. 318%N. [PubMed: 8832310]
205.
Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem--sleepwalking: a case report . Archives of Physical Medicine & Rehabilitation. 2005 Jun;86(6):1265–1266. [PubMed: 15954071]
206.
Askew JP. Zolpidem addiction in a pregnant woman with a history of second-trimester bleeding . Pharmacotherapy. 2007 Feb;27(2):306–308. [PubMed: 17253922]
207.
Cubala WJ, Landowski J. Seizure following sudden zolpidem withdrawal . Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2007 Mar 30;31(2):539–540. [PubMed: 16950552]
208.
de Haas S, Dingemanse J, Hoever P, Cohen A, van Gerven J. Pseudohallucinations after zolpidem intake: a case report . Journal of Clinical Psychopharmacology. 2007 Dec;27(6):728–730. [PubMed: 18004155]
209.
Kito S, Koga Y. Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: a possible interaction . International Psychogeriatrics. 2006 Dec;18(4):749–751. [PubMed: 17026779]
210.
Letsas KP, Filippatos GS, Kounas SP, Efremidis M, Sideris A, Kardaras F. QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone. Cardiology. 2006;105(3):146–147. [see comment] [PubMed: 16449812]
211.
Najjar M. Zolpidem and amnestic sleep related eating disorder . Journal of Clinical Sleep Medicine. 2007 Oct 15;3(6):637–638. [PMC free article: PMC2045714] [PubMed: 17993047]
212.
Sharan P, Bharadwaj R, Grover S, Padhy SK, Kumar V, Singh J. Dependence syndrome and intoxication delirium associated with zolpidem . National Medical Journal of India. 2007 Jul-Aug;20(4):180–181. [PubMed: 18085123]
213.
Tsai M-J, Tsai Y-H, Huang Y-B. Compulsive activity and anterograde amnesia after zolpidem use . Clinical Toxicology: The Official Journal of the American Academy of Clinical Toxicology & European Association of Poisons Centres & Clinical Toxicologists. 2007;45(2):179–181. [PubMed: 17364638]
214.
Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder . Archives of General Psychiatry. 2008 May;65(5):551–562. [PubMed: 18458207]
215.
Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep and Breathing. 2008 [PubMed: 18584227]
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK47211

Views

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...